Section Arrow
Quote
HROW.NASDAQ
- Harrow
Quotes are at least 15-min delayed:2026/05/19 01:55 EDT
Regular Hours
Last
 30.9
-0.31 (-0.99%)
Day High 
31.68 
Prev. Close
31.21 
1-M High
42.13 
Volume 
746.94K 
Bid
30.93
Ask
31.3
Day Low
30.56 
Open
31.07 
1-M Low
28.5401 
Market Cap 
1.16B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 35.72 
20-SMA 37.92 
50-SMA 36.71 
52-W High 54.85 
52-W Low 25.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.38/1.00
Enterprise Value
1.41B
Balance Sheet
Book Value Per Share
0.77
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
272.30M
Operating Revenue Per Share
2.76
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SBFMSunshine Biopharma Inc0.51+0.2259+79.51%-- 
HIMSHims & Hers Health22.29-2.76-11.02%-- 
ESPREsperion Therapeutics3.13+0.01+0.32%-- 
CGCCanopy Growth Corp0.9823-0.0577-5.55%-- 
VTRSViatris16.5+0.02+0.12%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.